Scalper1 News
Specialty-drug maker and IBD 50 stock Endo International (ENDP) beat Wall Street’s Q2 expectations Monday, but didn’t change its guidance as it digests a major acquisition. Endo earnings from continuing operations rose 21% over the year-earlier quarter to $1.08 a share, beating analysts’ consensus by 6 cents, according to Thomson Reuters. Revenue increased 24% to $735 million, about $7 million above consensus. The company left in place its Scalper1 News
Scalper1 News